Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis

Zheng Sean L.; Roddick Alistair J.; Aghar-Jaffar Rochan; Shun-Shin Matthew J.; Francis Darrel; Oliver Nick; Meeran Karim

首页> 外文期刊>JAMA: the Journal of the American Medical Association >Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis

【24h】

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis

机译：使用钠 - 葡萄糖Cotorangerper 2抑制剂，胰高血糖素样肽1激动剂和二肽基肽酶4抑制剂，患有2型糖尿病患者的所有导致死亡率的抑制剂是系统的评价和荟萃分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

IMPORTANCE The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors for treatment of type 2 diabetes is unknown.

机译：重要性葡萄糖COT转折剂2（SGLT-2）抑制剂，胰高血糖素样肽1（GLP-1）激动剂和二肽基肽酶4（DPP-4）抑制剂用于治疗2型糖尿病的比较临床疗效是未知的。

著录项

来源
《JAMA: the Journal of the American Medical Association》 |2018年第15期|共12页
作者
Zheng Sean L.; Roddick Alistair J.; Aghar-Jaffar Rochan; Shun-Shin Matthew J.; Francis Darrel; Oliver Nick; Meeran Karim;
展开▼
作者单位

Imperial Coll Healthcare NHS Fdn Trust Dept Endocrinol London England;

Kings Coll London Fac Life Sci &

Med London England;

Imperial Coll Healthcare NHS Fdn Trust Dept Endocrinol London England;

Imperial Coll London London England;

Imperial Coll London London England;

Imperial Coll Healthcare NHS Fdn Trust Dept Endocrinol London England;

Imperial Coll Healthcare NHS Fdn Trust Dept Endocrinol London England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis [J] . Zheng Sean L., Roddick Alistair J., Aghar-Jaffar Rochan, JAMA: the Journal of the American Medical Association . 2018,第15期

机译：使用钠 - 葡萄糖Cotorangerper 2抑制剂，胰高血糖素样肽1激动剂和二肽基肽酶4抑制剂，患有2型糖尿病患者的所有导致死亡率的抑制剂是系统的评价和荟萃分析
2. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (vol 37, pg 777, 2019) [J] . Hong Dongzhe, Si Lei, Jiang Minghuan, PharmacoEconomics . 2019,第12期

机译：钠 - 葡萄糖Cotroansporter-2（SGLT2）抑制剂，胰高血糖素样肽-1（GLP-1）受体激动剂和二肽基肽酶-4（DPP-4）抑制剂的成本有效性：系统评价（Vol 37，PG 777， 2019）
3. Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials [J] . Lu Ding, Bang Sun, Xinhua Xiao International journal of endocrinology . 2020,第2期

机译：比较胰高血糖素肽1受体激动剂与钠葡萄糖Cotroangerporter 2抑制剂的肥胖型糖尿病患者的疗效和安全性，对二甲双胍的不受控制的糖尿病患者：随机临床试验的系统审查和荟萃分析
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. Risk of Any Hypoglycemia with New Antihyperglycemic Agents in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis [D] . Kamalinia, Sanaz. 2019

机译：患有2型糖尿病患者的新抗血糖药物的任何低血糖症的风险：系统审查和荟萃分析
6. Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials [O] . Lu Ding, Bang Sun, Xinhua Xiao 2020

机译：比较胰高血糖素肽1受体激动剂与钠葡萄糖Cotroangerporter 2抑制剂的肥胖型糖尿病患者的疗效和安全性对二甲双胍的不受控制的糖尿病患者：随机临床试验的系统审查和荟萃分析
7. Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review [O] . Dongzhe Hong, Lei Si, Minghuan Jiang, 2019

机译：校正至：钠葡萄糖Cotoransporter-2（SGLT2）抑制剂，胰高血糖素样肽-1（GLP-1）受体激动剂和二肽基肽酶-4（DPP-4）抑制剂的成本有效性：系统审查

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis

摘要

著录项

相似文献

相关主题

期刊订阅